Join
Live feed
·
PRReleasevia Quantisnow
Sionna Therapeutics Inc. logo

Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis

ByQuantisnow·Wall Street's wire, on your screen.
SION· Sionna Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SION (Sionna Therapeutics Inc.) and more on Quantisnow.